Sign inJoin waitlistJoin the waitlist

SF

Samuel Funt

Assistant Attending Physician · New York Presbyterian Hospital

Credentials: · · · · ·

History

New York Presbyterian Hospital
Present

Memorial Sloan Kettering Cancer Center
2014–2016
Internal Medicine
New York Presbyterian Hospital
2011–2014
Emory University School of Medicine
2006–2010

Research

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
Journal of Clinical Oncology · 2018 · 441 citations
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis
PLoS Medicine · 2017 · 290 citations
Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice
Arteriosclerosis · 2011 · 182 citations

DB
Dean Bajorin
36 papers
Darren Feldman
35 papers
GI
Gopa Iyer
28 papers
HA
Hikmat Al-Ahmadie
27 papers
JS
Joel Sheinfeld
21 papers
JR
Jonathan Rosenberg
20 papers
David Solit
19 papers
MT
Min Yuen Teo
18 papers
VR
Victor Reuter
17 papers
Jonathan Rosenberg
15 papers
Richard Matulewicz
15 papers · 10 as a fellow
BB
Bernard Bochner
14 papers

Clinical trials

A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma
Principal investigator · Recruiting
Memorial Sloan Kettering Cancer Center
2026–2028
Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2018–2021
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2017–2026
A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2017–2027